EMA Adopts a Positive Opinion for Biosimilar Denosumab By Ogkologos - May 28, 2025 731 0 Facebook Twitter Google+ Pinterest WhatsApp Jubereq is a biosimilar of Xgeva, which was authorised in the EU in 2011 Source RELATED ARTICLESMORE FROM AUTHOR New Targeted Therapy Shows Promising Early Results in Advanced Pancreatic Cancer FDA Approves Pivekimab Sunirine-pvzy for Blastic Plasmacytoid Dendritic Cell Neoplasm, an Ultra-Rare Haematologic Malignancy Ivonescimab Plus Chemotherapy Improves OS Compared with Tislelizumab Plus Chemotherapy in Previously Untreated Patients with Advanced Squamous NSCLC MOST POPULAR Datopotamab Deruxtecan Shows Promising Activity in Heavily Pretreated Advanced HR-positive/HER2-negative and... May 7, 2024 NHS staff shortages: What’s needed to build a sustainable cancer workforce? October 12, 2020 Self-Dissolving Cracker Makes Swallowing Easier for People Struggling with Dysphagia July 13, 2021 10-Year Data Underscore How ICI Therapy Has Helped to Change the... October 10, 2024 Load more HOT NEWS FDA Approves New Interchangeable Biosimilar to Pertuzumab Mom Of Three Fought Breast Cancer, Drought, And Australia Bushfires In... Miss New Jersey Collegiate USA Uses Her Prestigious Position to Shed... My Path to Becoming a Radiation Therapist
